Advanced Oncotherapy #AVO – Completion of the Subscription Agreement

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that in relation to the announcement dated 7 December 2017 and following the passing of the resolution proposed for the vote of the Company’ shareholders on 23 January 2018, the Company has been informed by Yantai Cipu that the Chinese […]

Advanced Oncotherapy #AVO – Result of GM

Advanced Oncotherapy plc (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the General Meeting held earlier today, all resolutions were duly passed. For further information contact: Advanced Oncotherapy Plc www.avoplc.com Dr. Michael Sinclair, Executive Chairman Tel: +44 20 3617 8728 Nicolas Serandour, CEO Stockdale Securities (Nomad & Joint Broker) Antonio Bossi […]

Advanced Oncotherapy #AVO – Dr Enrico Vanni director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday Dr Enrico Vanni, Non-Executive Director of the Company purchased 40,000 ordinary shares of 25 pence in the Company at a price of 54.5 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 1,263,946 Ordinary Shares, representing 1.56% of the […]

Advanced Oncotherapy #AVO – Notice of General Meeting

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that a circular convening the Company’s General Meeting to be held at the Royal Institute of British Architects, 66 Portland Place, London W1B 1AD at 10:00am on Tuesday, 23 January 2018, in relation to the transactions announced on 7 December 2017 has […]

Advanced Oncotherapy #AVO – Hardman Research: Distribution agreement and capital increase

Advanced Oncotherapy #AVO – Hardman Research: Distribution agreement and capital increase Distribution agreement and capital increase: AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world-renowned CERN. Major milestones have been achieved in 2017 and the company remains on track with its development plan to deliver […]

Nicolas Serandour, CEO of Advanced Oncotherapy #AVO discusses Yantai deal & £37m equity investment with BRR Media

Nicolas Serandour, CEO of Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, announces that they have signed an exclusive distribution agreement with Yantai CIPU Medical Technology to market and sell Advanced Oncotherapy’s LIGHT system across China, Macau, Taiwan, Hong-Kong and South Korea. At the same time, the Company has secured £20.9 […]